How OVA1 Works

With a comprehensive 5-biomarker panel, OVA1 can detect tumor-secreted proteins while measuring the host response to ovarian cancer.

The OVA1 test combines 5 biomarkers, including:

  • Beta-2 microglobulin and CA 125-II are both up-regulated
  • apolipoprotein A1, Prealbumin, and transferrin are all down-regulated.

The addition of the 4 biomarkers to CA 125-II identify a high percentage of cancers missed by CA 125 alone. The immunoassay results of the individual OVA1 components are combined by a proprietary software algorithm called OvaCalc®. The clinical result is reported as a number that ranges from 0 to 10.

The combination of OVA1 and the physician’s clinical impression identified 96% of all ovarian cancers studied

Guidelines for treating women with an ovarian mass1,2

Guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Society of Gynecologic Oncologists (SGO), and the National Comprehensive Cancer Network (NCCN) recommend that women with an ovarian mass that is suspicious for cancer be under the care of a gynecologic oncologist.

The Society of Gynecologic Oncologists (SGO) comments on OVA13

A press release from September 2009 issued by the Society of Gynecologic Oncologists recognized the importance of OVA1 stating that it "...may help healthcare providers better detect when referral to a gynecologic oncologist is indicated." [Full SGO statement]